Recently, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the investigational antiviral drug remdesivir for the treatment of hospitalized adults and children with COVID-19.

The FDA notes that while there is limited information about the effectiveness of remdesivir, the drug has demonstrated in a clinical trial to shorten the time to recovery in some patients.